To highlight current evidence pertaining to the measurement methods and prevalence of high on-treatment platelet reactivity (HTPR) in patients with PAD, as well as to evaluate the relationship between HTPR and recurrent adverse cardiovascular and limb events in PAD patients.
Methods
A systematic review of English-language literature on HTPR in patients with PAD. An electronic literature search of PubMed and Medline was performed in May 2021.
Results
A total of 29 studies with a total number of 11,201 patients with PAD were identified. HTPR during clopidogrel treatment ranges from 9.8 to 77%, and during aspirin treatment ranges from 4.1 to 50% of PAD patients. HTPR was associated with adverse clinical outcomes. The need for limb revascularisation was higher in patients with HTPR during clopidogrel use. Similarly, HTPR during aspirin use in the PAD population was predictive of adverse cardiovascular events (HR 3.73; 95% CI, 1.43–9.81; p = .007). A wide range of techniques were applied to measure platelet resistance, without consensus on cut-off values. Furthermore, differing patient populations, a variety of antiplatelet regimens, and differing clinical endpoints highlight the high degree of heterogeneity in the studies included in this review.
Conclusion
No consensus on technique or cut-off values for HTPR testing has been reached. Patients with HTPR are potentially at a greater risk of adverse limb-related and cardiovascular events than patients sensitive to antiplatelet therapy illustrating the need for clinical implementation of HTPR testing. Future research must aim for consistent methodology. Adaptation of antiplatelet therapy based on HTPR results requires further exploration.
AboyansVRiccoJ-BBartelinkM-LEL, et al.Editor’s Choice – 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg2018; 55(3): 305–368.
2.
GremmelTKoppensteinerRPanzerS. Comparison of aggregometry with flow cytometry for the assessment of agonists’-induced platelet reactivity in patients on dual antiplatelet therapy. PLoS One2015; 10(6): e0129666.
3.
ZhangJ-JGaoX-FGeZ, et al.High platelet reactivity affects the clinical outcomes of patients undergoing percutaneous coronary intervention. BMC Cardiovasc Disord2016; 16(1): 240.
4.
GurbelPABlidenKPGuyerK, et al.Platelet reactivity in patients and recurrent events post-stenting: results of the prepare post-stenting study. J Am Coll Cardiol2005; 46(10): 1820–1826.
5.
SnoepJDMHovensMMCMDEikenboomJCJMDP, et al.Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J2007; 154(2): 221–231.
6.
SofiFMarcucciRGoriAM, et al.Clopidogrel non-responsiveness and risk of cardiovascular morbidity an updated meta-analysis. Thromb Haemost2010; 103(4): 841–848.
7.
KrasopoulosGBristerSJBeattieWS, et al.Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ2008; 336(7637): 195–198.
8.
GuirgisMThompsonPJansenS. Review of aspirin and clopidogrel resistance in peripheral arterial disease. J Vasc Surg2017; 66(5): 1576–1586.
9.
WhitingPFRutjesAWSWestwoodMEQUADAS-2 Group, et al.QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med2011; 155(8): 529–536.
10.
MoherDShamseerLClarkeMPRISMA-P Group, et al.Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev2015; 4(1): 1–60.
11.
AkinosoglouKPerperisATheodorakiS, et al.Sepsis favors high-on-clopidogrel platelet reactivity. Platelets2018; 29(1): 76–78.
12.
GuptaRKirtaneAJOzanMO, et al.platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents in subjects with peripheral arterial disease: analysis from the adapt-des study (assessment of dual antiplatelet therapy with drug-eluting stents). Circ Cardiovasc Interv2017; 10(3): e004904.
13.
Hernandez-SuarezDFScottSATomeyMI, et al.Clinical determinants of clopidogrel responsiveness in a heterogeneous cohort of Puerto Rican Hispanics. Ther Adv Cardiovasc Dis2017; 11(9): 235–241.
14.
KhanHGallantRCZamzamA, et al.Personalization of aspirin therapy ex vivo in patients with atherosclerosis using light transmission aggregometry. Diagnostics2020; 10(11): 871.
15.
MazurPFrołowMNiżankowskiR, et al.Impaired responsiveness to clopidogrel and aspirin in patients with recurrent stent thrombosis following percutaneous intervention for peripheral artery disease. Platelets2013; 24(2): 151–155.
16.
BorowskiGNowaczyńskaA. Assessment of platelet function and resistance to aspirin and clopidogrel in patients with peripheral arterial disease undergoing percutaneous transluminal angioplasty. Acta Angiol2021; 26(4): 119–128.
17.
BuschLSternMDannenbergL, et al.Impact of high on-treatment platelet reactivity after angioplasty in patients with peripheral arterial disease. Platelets2021; 32(3): 391–397.
18.
CassarKBachooPFordI, et al.Variability in responsiveness to clopidogrel in patients with intermittent claudication. Eur J Vasc Endovasc Surg2006; 32(1): 71–75.
19.
GrifoniEGoriAMGiustiB, et al.On-treatment platelet reactivity is a predictor of adverse events in peripheral artery disease patients undergoing percutaneous angioplasty. Eur J Vasc Endovasc Surg2018; 56(4): 545–552.
20.
GuoBTanQGuoD, et al.Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in-stent restenosis after endovascular treatment of lower extremity peripheral arterial disease. J Vasc Surg2014; 60(4): 993–1001.
21.
HartingerJNovotnyRBilkovaJ, et al.Role of dipyrone in the high on-treatment platelet reactivity amongst acetylsalicylic acid-treated patients undergoing peripheral artery revascularisation. Med Princ Pract2018; 27(4): 356–361.
22.
KarnabatidisDSpiliopoulosSPastromasG, et al.Prevalence of nonresponsiveness to aspirin in patients with symptomatic peripheral arterial disease using true point of care testing. Cardiovasc Intervent Radiol2014; 37(3): 631–638.
23.
LeeJChengNTaiH, et al.CYP2C19 polymorphism is associated with amputation rates in patients taking clopidogrel after endovascular intervention for critical limb ischaemia. Eur J Vasc Endovasc Surg2019; 58(3): 373–382.
24.
LeunissenTCPeeters WeemSMUrbanusRT, et al.High on-treatment platelet reactivity in peripheral arterial disease: a pilot study to find the optimal test and cut off values. Eur J Vasc Endovasc Surg2016; 52(2): 198–204.
25.
LinnemannBProchnowSManiH, et al.Variability of non-response to aspirin in patients with peripheral arterial occlusive disease during long-term follow-up. Ann Hematol2009; 88(10): 979–988.
26.
LinnemannBSchwonbergJRechnerAR, et al.Assessment of clopidogrel non-response by the PFA-100 system using the new test cartridge INNOVANCE PFA P2Y. Ann Hematol2010; 89(6): 597–605.
27.
PastromasGSpiliopoulosSKatsanosK, et al.Clopidogrel responsiveness in patients undergoing peripheral angioplasty. Cardiovasc Intervent Radiol2013; 36(6): 1493–1499.
28.
SaundersJNambiVKimballKTELIMIT Investigators, et al.Variability and persistence of aspirin response in lower extremity peripheral arterial disease patients. J Vasc Surg2011; 53(3): 668–675.
29.
SpiliopoulosSPastromasGKatsanosK, et al.Platelet responsiveness to clopidogrel treatment after peripheral endovascular procedures: the PRECLOP study: clinical impact and optimal cutoff value of on-treatment high platelet reactivity. J Am Coll Cardiol2013; 61(24): 2428–2434.
30.
SpiliopoulosSKatsanosKPastromasG, et al.Initial experience with ticagrelor in patients with critical limb ischemia and high on-clopidogrel platelet reactivity undergoing complex peripheral endovascular procedures. Cardiovasc Intervent Radiol2014; 08.
31.
TepeGBantleonRBrechtelK, et al.Management of peripheral arterial interventions with mono or dual antiplatelet therapy--the MIRROR study: a randomised and double-blinded clinical trial. Eur Radiol2012; 22(9): 1998–2006.
32.
YeoKKArmstrongEJLópezJE, et al.Aspirin and clopidogrel high on-treatment platelet reactivity and genetic predictors in peripheral arterial disease. Catheter Cardiovasc Interv2018; 91(7): 1308–1317.
33.
ClavijoLCDhillonAAl-AsadyN, et al.Switch to Ticagrelor in critical limb ischemia antiplatelet study (STT-CLIPS). Cardiovasc Revasc Med2018; 19(3 Pt B): 319–323.
34.
DhillonASCaroJTunH, et al.Therapeutic window of clopidogrel and ticagrelor in patients with critical limb-threatening ischemia. J Cardiovasc Pharmacol Ther2020; 25(2): 158–163.
35.
ClavijoLCAl-AsadyNDhillonA, et al.Prevalence of high on-treatment (aspirin and clopidogrel) platelet reactivity in patients with critical limb ischemia. Cardiovasc Revasc Med2018; 19(5 Pt A): 516–520.
36.
Hernandez-SuarezDFNúñez-MedinaHScottSA, et al.Effect of cilostazol on platelet reactivity among patients with peripheral artery disease on clopidogrel therapy. Drug Metab Pers Ther2018; 33(1): 49–55.
37.
PasalaTHooJSLockhartMK, et al.Aspirin resistance predicts adverse cardiovascular events in patients with symptomatic peripheral artery disease. Tex Heart Inst J2016; 43(6): 482–487.
38.
LinnemannBSchwonbergJToennesSW, et al.Variability of residual platelet function despite clopidogrel treatment in patients with peripheral arterial occlusive disease. Atherosclerosis2010; 209(2): 504–509.
39.
MadsenEHGehrNRJohannesenNL, et al.Platelet response to aspirin and clopidogrel in patients with peripheral atherosclerosis. Platelets2011; 22(7): 537–546.
40.
GentMBeaumontDBlanchardJ, et al.A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). The Lancet (British edition)1996; 348(9038): 1329–1339.
41.
WismanPPRoestMAsselbergsFW, et al.Platelet-reactivity tests identify patients at risk of secondary cardiovascular events: a systematic review and meta-analysis. J Thromb Haemost2014; 12(5): 736–747.
42.
FiolakiAKatsanosAHKyritsisAP, et al.High on treatment platelet reactivity to aspirin and clopidogrel in ischemic stroke: a systematic review and meta-analysis. J Neurol Sci2017; 376: 112–116.
43.
LeeSLeeSChunW, et al.Clopidogrel monotherapy in patients with and without on-treatment high platelet reactivity: a SMART-CHOICE substudy. EuroIntervention2021; 17(11): e888–e897.
44.
BrarSSten BergJMarcucciR, et al.Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention a collaborative meta-analysis of individual participant data. J Am Coll Cardiol2011; 58(19): 1945–1954.
45.
PriceMJBergerPBTeirsteinPSGRAVITAS Investigators, et al.Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the gravitas randomized trial. JAMA2011; 305(11): 1097–1105.
46.
DroppaMTschernowDMüllerKAL, et al.Evaluation of clinical risk factors to predict high on-treatment platelet reactivity and outcome in patients with stable coronary artery disease (PREDICT-STABLE). PLoS One2015; 10(3): e0121620.
47.
DesaiNRMDMPHMegaJLMDMPHJiangSMPH, et al.Interaction between cigarette smoking and clinical benefit of clopidogrel. J Am Coll Cardiol2009; 53(15): 1273–1278.
48.
JiangX-LSamantSLeskoLJ, et al.Clinical pharmacokinetics and pharmacodynamics of clopidogrel. Clin Pharmacokinet2015; 54(2): 147–166.
49.
CaiZCaiDWangR, et al.Cost-effectiveness of CYP2C19 genotyping to guide antiplatelet therapy for acute minor stroke and high-risk transient ischemic attack. Sci Rep2021; 11(1): 7383.
50.
ClaassensDMFVosGJABergmeijerTO, et al.A genotype-guided strategy for oral p2y(12) inhibitors in primary PCI. N Engl J Med2019; 381(17): 1621–1631.
51.
XiZFangFWangJ, et al.CYP2C19 genotype and adverse cardiovascular outcomes after stent implantation in clopidogrel-treated Asian populations: A systematic review and meta-analysis. Platelets2019; 30(2): 229–240.
52.
ZhangLYangJZhuX, et al.Effect of high-dose clopidogrel according to CYP2C192 genotype in patients undergoing percutaneous coronary intervention– a systematic review and meta-analysis. Thromb Res2015; 135(3): 449–458.
53.
ErlingeDJamesSDuvvuruS, et al.Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease. Thromb Haemost2014; 111(5): 943–950.
54.
BonelloLArmeroSAit MokhtarO, et al.Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2c192loss of function polymorphism. J Am Coll Cardiol2010; 56(20): 1630–1636.
55.
PatelMRBeckerRCWojdylaDM, et al.Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: data from the PLATO Trial. Eur J Prev Cardiol2015; 22(6): 734–742.
56.
HiattWRFowkesFGRHeizerGEUCLID Trial Steering Committee and Investigators, et al.Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N Engl J Med2017; 376(1): 32–40.
57.
BergerJSAbramsonBLLopesRD, et al.Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial. Vasc Med2018; 23(6): 523–530.
58.
WallentinLBeckerRCBudajACannonCPEmanuelssonHHeldCHorrowJHustedSJamesSKatusHMahaffeyKWSciricaBMSkeneAStegPGStoreyRFHarringtonRAPLATO InvestigatorsFreijAThorsénM. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med2009; 361(11): 1045–1057.
59.
QamarAMorrowDACreagerMA, et al.Effect of vorapaxar on cardiovascular and limb outcomes in patients with peripheral artery disease with and without coronary artery disease: Analysis from the TRA 2°P-TIMI 50 trial. Vasc Med2020; 25(2): 124–132.
60.
GalliMBenenatiSFranchiF, et al.Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials. Eur Heart J2022; 43(10): 959–967.
61.
MajumdarMWallerDPoyantJ, et al.Variability of antiplatelet response in patients with peripheral artery disease. J Vasc Surg2023; 77: 208–215.e3.
62.
PetrovićJPešićVLauschkeVM. Frequencies of clinically important CYP2C19 and CYP2D6 alleles are graded across Europe. Eur J Hum Genet2020; 28(1): 88–94.
63.
ZlatanovicPWongKHFKakkosSK, et al.A systematic review and meta-analysis on the impact of high on-treatment platelet reactivity on clinical outcomes for patients taking ADP receptor inhibitors following lower limb arterial endovascular intervention. Eur J Vasc Endovasc Surg2022; 63(1): 91–101.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
